Following the ongoing decline in COVID-19 product sales, Pfizer (PFE.US) is beginning to exhibit indications of more consistent growth. The pharmaceutical giant posted second-quarter fiscal 2026 revenue of $15 billion, a 1% increase on an operational basis year-over-year; excluding Comirnaty and Paxlovid, revenue climbed 5% operationally. Concurrently, the company raised the midpoint of its full-year revenue guidance. Driven by stronger-than-expected performance in non-COVID products, Pfizer lifted its 2026 annual revenue outlook from the prior $59.5 billion to $62.5 billion range to a new span of $60.5 billion to $62.5 billion, representing a $500 million increase at the midpoint. The firm also reaffirmed its full-year adjusted earnings per share guidance of $2.80 to $3.00, closely aligning with the consensus estimate of $2.95. However, the company's recovery still confronts a significant challenge—whether growth from new products and cost reductions can offset the impending patent losses across several of its established medications.

What bolsters the bull case is that Pfizer's reliance on unpredictable COVID-related sales is diminishing, as its non-COVID portfolio now fuels growth. Newly launched and acquired drugs generated $3.2 billion in quarterly revenue, up 18% on an operational basis. The company has also revised its 2026 COVID-19 revenue projection downward to approximately $4 billion, largely due to weak demand for Paxlovid. Furthermore, the company's expansion is becoming increasingly diversified. Padcev continues to gain market share in bladder cancer, while Vyndaqel benefits from improved diagnostic rates and rising international demand. Padcev revenue grew 23% operationally to $667 million, while the Vyndaqel franchise delivered $1.76 billion, an 8% operational increase. This diversification is crucial, as the company requires multiple products to underpin its post-pandemic rebound rather than relying on a single blockbuster. Pfizer has also broadened its cost-saving targets and remains on track, anticipating approximately $5.7 billion in net savings by the end of 2026. By 2029, the company projects cumulative net savings of $6.7 billion from cost-cutting measures, which are expected to offset the COVID-related revenue decline and restore sustainable growth. These savings are poised to support margins and free up resources for investments in oncology and obesity, even as overall revenue growth stays modest.

On the bearish side, Pfizer's revenue rose just 1% operationally, with favorable currency fluctuations contributing to the reported growth. This underscores that the turnaround has yet to produce robust company-wide organic expansion. Pfizer also reported a GAAP pre-tax loss from continuing operations, partly attributable to impairment, legal, restructuring, and acquisition-related charges. Consequently, reported profitability remains weighed down by restructuring and portfolio-related costs. Another critical issue for investors is the looming patent cliff. Pfizer anticipates significant revenue pressure from multiple patent expirations between 2026 and 2030, with key products facing competition including Eliquis, Ibrance, and Xtandi. The 2026 full-year guidance indicates that recent and expected competition—from generics and biosimilars for products that have lost or are about to lose patent or regulatory exclusivity—is projected to have an unfavorable impact of roughly $1.1 billion on revenue. Although Padcev and Vyndaqel are growing, investors still lack concrete evidence that Pfizer's new product pipeline can replace the combined revenue that mature drugs are set to lose to patent expirations.

Hedge fund sentiment offers another lens on Pfizer's outlook. According to Insider Monkey's database tracking 1,022 hedge funds, the number holding Pfizer stock ticked up slightly from 81 in the fourth quarter of 2025 to 83 in the first quarter of 2026. While this marginal increase is too small to signal a decisive shift in institutional conviction, it does indicate that hedge fund interest has remained broadly stable and slightly positive as Pfizer progresses with its turnaround.

In summary, as Pfizer expands its non-COVID portfolio, sees growth from products like Padcev and Vyndaqel, and management continues to lower the cost base, the turnaround story is becoming increasingly credible. Yet, the recovery remains incomplete. Operational revenue growth is still modest, and impending patent expirations could place substantial strain on several mature franchise businesses. Pfizer's leaner cost structure affords some breathing room, but the long-term investment thesis ultimately hinges on one pivotal question: can the company's new drugs scale sufficiently to replace the revenue it is bracing to lose?